Introduction
Transmissible spongiform encephalopathies (TSEs) or prion diseases are a group of fatal neurodegenerative disorders that include Creutzfeldt-Jakob disease (CJD) and Kuru in humans, bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep and goats, and chronic wasting disease (CWD) in deer. The causative agent is widely believed to be a misfolded isoform of the normal, ubiquitously expressed cellular protein, PrP c , which converts to the pathogenic form (PrP Sc ) and accumulates largely in the central nervous system (Prusiner, 1998) .
Prion diseases are associated with pathological changes in the brain, which may include vacuolation, neuronal loss, astrocytosis, and amyloid plaque formation. The period between infection and the development of clinical signs is usually prolonged, and during this period, there is often progressive accumulation of infectivity and PrP Sc in lymphoid tissue. While infection of the lymphoid tissue has no apparent deleterious effects on the health of the affected individual, it is likely to be a significant reservoir of infectivity, which may be spread through blood and blood products. Indeed, infectivity in blood was recently demonstrated in both scrapie-and BSE-infected sheep (Houston et al., 2000 (Houston et al., , 2008 Hunter et al., 2002) , in deer with CWD (Mathiason et al., 2009) , and in rodent models of prion disease (Diringer, 1984; Gregori et al., 2006a,b; Gregori and Rohwer, 2007; Holada et al., 2002; Manuelidis et al., 1978) . In addition, blood transfusion or blood products have been implicated in the transmission of vCJD to four human recipients (Hewitt, 2006; HPA, 2007; Llewelyn et al., 2004; Peden et al., 2004; Wroe et al., 2006) .
Currently, there is no widely available or validated live animal blood test for prion diseases, possibly due to the anticipated low titre of PrP Sc in circulating blood (Brown et al., 2001) . Nevertheless, using protein misfolding cyclic amplification (PMCA), PrP Sc has been shown to be associated with both the leucocyte and plasma fractions of the blood in rodent models of disease (Castilla et al., 2005; Murayama et al., 2007; Saa et al., 2006) , and with the leucocyte fraction of blood from scrapie-exposed sheep (Thorne and Terry, 2008) . More recently, we have described an immunoassay for the direct detection of PrP Sc associated with peripheral blood mononuclear cells (PBMC) during both the preclinical and clinical phases of the disease (Terry et al., 2009) . The progressive increase in prions observed during the course of disease is consistent with recently published transfusion studies showing increased infectivity (Houston et al., 2008) .
During scrapie infection, blood leucocytes are likely to be a key player in the dissemination of prions during disease since they recirculate through the lymphoreticular system (LRS). Furthermore, PBMC from both scrapie-infected and uninfected sheep express surface PrP c (Barclay et al., 2002; Halliday et al., 2005; Herrmann et al., 2001) , which is a requirement for prion infection (Brown et al., 1999; Bueler et al., 1993; Kaeser et al., 2001) . However, it is unclear which leucocyte subset(s) is able to accumulate prions. Variation in surface PrP c expression levels could modify a cell subset's ability to accumulate or replicate the prion agent. For example, in sheep, CD4 + T lymphocytes express relatively low levels of surface PrP c (Rocchi et al., 2007) while CD21-expressing lymphocytes show increased levels of expression (Halliday et al., 2005) . Contents lists available at ScienceDirect Virology j o u r n a l h o m e p a g e : w w w. e l s e v i e r. c o m / l o c a t e / y v i r o To expand our understanding of blood-borne infection during prion disease, we have investigated the ability of different leucocyte subsets in the blood of scrapie-exposed sheep to sequester PrP Sc . These studies will provide clues to the role of different leucocyte subsets during disease pathogenesis and markers for more sensitive diagnostic tests. Furthermore, in humans, these cells may represent therapeutic targets.
Results

PrP
Sc is associated with MHC class II DQ-expressing cells in the blood from sheep naturally infected with scrapie and experimentally infected with BSE, during both the clinical and preclinical phases of the disease Previous studies have implicated both B cells and cells of the myeloid lineage, including conventional dendritic cells (DC), in the dissemination of prions throughout the lymphoreticular system (Aucouturier and Carnaud, 2002; Aucouturier et al., 2001; Brown, 1997; Flores-Langarica et al., 2009; Frigg et al., 1999; Huang et al., 2002; Klein et al., 1997 Klein et al., , 1998 Levavasseur et al., 2007; Mabbott et al., 2001; Raymond et al., 2007; Sethi et al., 2007; von Poser-Klein et al., 2008) . To investigate this in more detail, we determined whether PrP Sc partitions with PBMC that express MHC class II DQ (MHC II DQ), a marker constitutively expressed on both B cells and DC, from scrapie-and BSE-infected sheep.
Subpopulations of PBMC distinguished by the expression of MHC II DQ were separated from blood sampled from sheep naturally infected with scrapie (n = 11) or experimentally infected with BSE (n = 2), all showing clinical signs of disease at the time of sampling.
In VRQ/VRQ sheep, the assay signal observed in the MHC II DQconcentrated fraction was significantly higher than the signal in either the unseparated or depleted fraction and also when compared to the negative controls (Fig. 1A) . However, the signal observed in the MHC II DQ-depleted fraction did not differ significantly from the controls. Collectively, these data indicate that PrP Sc is specifically sequestered with MHC II DQ-expressing cells in scrapie-infected VRQ/VRQ sheep. In ARQ/VRQ sheep, a similar pattern of association was observed, and the PrP Sc signal was significantly higher in the MHC II DQ-concentrated fraction than in the depleted fraction, although no significant differences between cell fractions and the controls were found. Finally, a similar trend was observed between cell fractions from BSE infected ARQ/ARQ sheep, although again these differences were not found to be significantly different. It is possible that the lower signals obtained and/or the fewer cases examined in these two genotypes contributed to the inability to show a statistical difference between cell fractions and the corresponding controls. Importantly, PrP
Sc was not detected in either MHC II DQ-positive or -negative fractions from scrapie-free sheep (Fig. 1B) .
To determine whether PrP Sc is also associated with MHC II DQpositive cells during the preclinical phase of disease, blood was sampled monthly between 7 and 14 months of age inclusive (equivalent to 2-17 months before the onset of clinical signs) from five VRQ/VRQ scrapie-exposed sheep. Scrapie infection was confirmed in all five sheep by recto-anal mucosa-associated lymphoid tissue (RAMALT) biopsy and immunohistochemistry at 14 months of age (data not shown). We found that PrP Sc was detected in the MHC II DQ positive fraction in 3/5 sheep and was detected consistently at all time points in two sheep (sheep 2 and 5) (Fig. 1C) . Notably, 'sheep 2' (Brown et al., 1999; Kaeser et al., 2001 ) and mice devoid of PrP c are resistant to prion disease (Bueler et al., 1993) . Since PBMC subsets express different levels of surface PrP c (Halliday et al., 2005) , it is possible that different cell subsets might vary in their ability to support PrP Fig. 2A) . In scrapie-free sheep, this difference was also observed, but to a lesser extent. Heterogeneity of antibody binding was also observed, and core (Sha31) and octapeptide repeat (SAF32) epitopes were highly expressed while antibody FH11, which labels a region within the N-terminus, revealed lower levels of fluorescence. Reduced N-terminal labelling of the PrP protein was previously described by others and is likely to reflect either PrP truncation (Thackray et al., 2006) or masking of the epitope. Differences in PrP expression or epitope exposure were not observed between infected and control sheep; however, the high level of PrP c expressed on the cell surface may be masking detection of PrP Sc on scrapie-infected cells. We therefore cannot discount the possibility that PrP Sc is expressed on the surface of MHC II DQ-positive cells.
To ensure that the observed increase in assay signal associated with MHC II DQ positive cells is attributed to PrP Sc rather than the increased expression of PrP c , MHC II DQ positive cells from both scrapie-exposed and control sheep were analysed with increasing cell numbers (Fig. 2B ). The signal in the assay increased proportionally with increasing numbers of MHC II DQ cells from the scrapie-positive sheep. Conversely, no increase in signal was observed with MHC II DQ-positive cells from unexposed animals, even when 4 times more MHC II DQ cells were applied to the assay than required to give a signal from infected sheep. These data would therefore argue against detection of PrP c expressed by PBMC. Furthermore, previous studies of PBMC from over 100 unexposed sheep failed to detect signals above background levels (Terry et al., 2009 ).
Sc is not associated with PBMC expressing CD2 or CD14 but is sequestered with cells expressing surface immunoglobulin MHC II DQ is expressed on all sheep B cells (Puri et al., 1985) , but expression is rare on T cells from the peripheral blood (Dutia et al., 1993) . MHC II DQ is also expressed on cells of the monocyte/ macrophage lineage. To define more precisely the cells associated with PrP Sc , we examined the expression of the MHC II DQ molecule on CD2-positive T cells, CD14-positive monocytes, and surface immunoglobulin (sIg)-positive B cells from scrapie-infected sheep (n = 5) using flow cytometry. We also investigated the partitioning of PrP Sc with PBMC separated on the basis of expression of these lineage markers.
As previously described in uninfected sheep, the majority of B cells (96.1% ± 1.9%), but only a proportion of T cells (17.2% ± 3.8%) and CD14 cells (32.4% ± 6.4%), express MHC II DQ (Fig. 3A) . PrP Sc analysis of CD2 fractions from infected sheep showed a significantly higher signal in the unseparated and depleted fractions compared to CD2-concentrated cells, suggesting that PrP Sc partitions in the CD2- negative cell fraction. Moreover, the signal in the CD2-depleted fraction was significantly higher than that observed in the scrapie-free controls (Fig. 3Bi) . These data indicate that PrP Sc does not accumulate within peripheral blood T cells during scrapie infection, although we cannot rule out the possibility that T cells, which express the γ/δ Tcell receptor (but not CD2) (Mackay et al., 1989) , might contain PrP Sc .
Similarly, PrP
Sc was not detected in CD14-enriched cell fractions (Fig. 3Bii) . However, CD14 cells only constitute approximately 5% of all PBMC in sheep blood, and therefore, isolation of CD14-positive subsets from 10 8 PBMC yielded less than 3 × 10 6 CD14-positive cells. To obtain a signal above background 10 7 cells/well are required and therefore analysis of the CD14-enriched cells at matched cell numbers with CD14-depleted and unseparated PBMC did not give positive signals. However, when the number of CD14-depleted and unseparated cells per well was increased, the CD14-negative fraction gave a signal equal to or higher than the unseparated population of cells, indicating that most PrP Sc was contained within the CD14-negative population. Furthermore, given that the CD14-enriched fractions (at 3 × 10 6 cells) contain the equivalent number of CD14-positive cells expected to be found in approximately 6 × 10 7 unseparated PBMC, it is unlikely that the CD14-bearing monocytes are associated with the majority of PrP Sc in the blood. Nevertheless, given the difficulty of obtaining sufficient cells to analyse 10 7 cells per well, we cannot rule out the possibility that some signal is contained within the CD14 population.
Significantly higher levels of PrP Sc were associated with the VPM8-concentrated fraction relative to both VPM8-depleted fractions and the negative controls (Fig. 3Biii) . VPM8 is reactive with the sheep immunoglobulin light chain, indicating a direct association of PrP Sc with B lymphocytes in the blood of scrapie-infected sheep. A significant difference was also observed between the signal in the depleted fraction and the controls, and therefore, the possibility that prions might sequester in an additional cell population, albeit at low levels, cannot be ruled out.
PrP
Sc is associated with a subpopulation of B cells
Two subpopulations of B cells have been described in several species . In sheep, these cells are distinguished by their expression of CD21 and CD62L or CD11b and CD11c (Chevallier et al., 1998; Gupta et al., 1998; Young et al., 1997) , although it is unclear whether they represent exactly the same functional subsets as the B1 and B2 B-cell subsets described in mice 
i) anti-CD2 (T cells), (ii) anti-CD14 (monocytes), and (iii) VPM8 (sIg). (B) PrP
Sc content of fractionated PBMC separated on the basis of (i) expression of CD2 from three scrapie-infected sheep (one sheep was sampled during the preclinical phase), (ii) expression of CD14 from two VRQ/VRQ scrapie-infected sheep and one ARQ/ARQ animal, and (iii) expression of sIg (VPM8) from six VRQ/VRQ scrapie-infected sheep. Columns show the mean absorbance of all sheep tested. Cell fractions from each sheep were analysed at equivalent cell numbers (cells/ well × 10 6 ). For the CD14 fractions, the unseparated and depleted cell fractions were also analysed at higher cell numbers per well. Error bars represent + 1 SD. Statistical differences between the fractions from the infected sheep were determined by two-way ANOVA as shown in the figure. Also, the mean absorbency associated with the CD2-depleted fractions (p b 0.05) and the VPM8-unseparated (p b 0.01), -depleted (p b 0.05), and -concentrated (p b 0.001) fractions was significantly higher than PBMCs from scrapie-free sheep. Tung et al., 2006) . By flow cytometry, we showed that the majority of sheep peripheral blood B cells express CD11b (69.7% ± 5.9%), while 26.9% (±12.2%) express CD21. Furthermore, although these cell surface antigens largely delineate two reciprocal B-cell populations, the data presented here indicate coexpression of CD21 on approximately 12.9% (±5.2%) of CD11b-positive cells (Fig. 4A) . Subsequent analysis of CD11b-enriched cells showed that the assay signal was significantly higher than equivalent unseparated or CD11b-depleted populations suggesting that PrP Sc is principally associated with CD11b-enriched fractions (Fig. 4B) . However, the signal in all three fractions was found to be significantly higher than PBMCs from scrapie-free sheep, indicating that some residual signal may also be present in CD11b-depleted cells. To investigate this further, PBMCs were also separated based on the expression of CD11c, a marker expressed on the majority of CD11b cells (86.4% ± 3.7%, data not shown). Like CD11b, the signal in the CD11c-enriched fractions was significantly higher than seen in either the depleted or the unseparated cells, suggesting that PrP Sc is associated with these fractions. Furthermore, the signal obtained in the CD11c-depleted fraction was not significantly different from that seen in scrapie-free sheep. (Fig. 4C) . Taken together, these data indicate that PrP Sc is highly enriched in a fraction of B cells coexpressing both the CD11b and CD11c cell surface antigens. Three-colour flow cytometry confirmed that the majority of sIg/CD11b cells in blood from scrapieinfected sheep coexpress CD11c (Fig. 4D) .
Analysis of CD21-positive and -negative fractions showed variable partitioning of PrP Sc . In three sheep, the PrP Sc signal in the CD21-depleted and -concentrated fractions were similar, suggesting that both fractions have accumulated similar levels of prions (Fig. 5i) . However, in a fourth sheep, the majority of PrP Sc appeared to partition in the CD21-concentrated fraction (Fig. 5ii) , and in a fifth sheep, all cell-associated PrP Sc was present in the CD21-depleted fraction (Fig. 5iii) . The variable outcome does not appear to be dependent on the clinical status of the sheep since the two animals where PrP Sc was found in both CD21 fractions were reported to be clinical and preclinical, respectively (Fig. 5i) . Therefore, we conclude that PrP Sc does not appear to partition cleanly with either subset of B cells based on CD21 expression. This appears to contradict the CD11b and CD11c fractionation studies, although this may be explained by the observed overlap of CD21 expression with the CD11b/CD11c-positive subset. Finally, we examined whether PrP Sc was associated with fractions delineated by CD62L, a marker previously shown to be exclusively expressed by CD21 B cells (Gupta et al., 1998) . We confirmed that a proportion of CD21 B cells coexpress CD62L (45.7% ± 12.7%). We also observed that CD62L is expressed on a proportion of CD11b cells (14.42% ± 4.76%), although the majority of these cells is likely to be monocytes, since CD14 monocytes coexpress CD11b and CD62L (Bonneau et al., 2006) . Moreover, CD11b B cells are predominantly CD62L negative (Gupta et al., 1998) (Fig. 5) . Analysis of the PrP Sc content of the CD62L cell fractions resulted in two different patterns of reactivity, thus mirroring our observations following CD21 fractionation. In three of the four sheep, the result was clear: the CD62L-concentrated cells did not harbour any detectable PrP Sc , and all reactivity was located in the depleted cell fraction (Fig. 5) . However, in one sheep, the reverse was observed: the signal was statistically higher in the CD62L-concentrated fraction compared to controls, while the depleted fraction remained PrP Sc -negative (Fig. 5) .
Taken together, the data presented in this study suggest that the majority of detectable PrP Sc is associated with a subset of sIg expressing cells in the blood that coexpress MHC II DQ, CD11b and CD11c and also coexpress CD21 in some sheep. This phenotype is consistent with a subset of B cells, although we cannot rule out that other minor populations of cells sequester PrP sc , and this is under current investigation.
Discussion
In this report, we show that PrP
Sc is principally associated with B cells in the blood of sheep infected with scrapie. To our knowledge, this is the first report identifying a subset of blood leucocytes shown to concentrate prions. Others have attempted similar studies in human sporadic CJD and reported that PrP Sc is not associated with platelets, NK cells, CD8 + T cells, CD4 + T cells, B cells, monocytes, or granulocytes from the blood (Choi et al., 2009 ). This may, however, be 
(C) PrP
Sc association with B cells separated on the basis of the expression of CD62L (i) from three VRQ/VRQ scrapie-infected sheep (two samples during the preclinical phase) and (ii) from a single VRQ/VRQ scrapie-infected sheep also sampled during the preclinical phase. For figures Ai, Aii, and Ci where multiple sheep were examined, each column represents the mean absorbance value for total number of sheep tested, and error bars represent + 1 SD. However, for figures Aiii and Cii where a single sheep was analysed, error bars represent 1 SE and reflect the values obtained for replicate wells. Statistical differences between the fractions derived from several infected sheep were determined by two-way ANOVA as shown in the figure. Also, the mean absorbency associated with the CD21-unseparated fraction was significantly higher than in PBMCs from scrapie free sheep (p b 0.05).
due to the differences in pathogenesis of the two diseases: sCJD has not been implicated in sources of infectivity in blood transfusions (Hewitt, 2006) and has a different pattern of pathogenesis that often excludes infectivity in the LRS. It is therefore possible that PrP
Sc is not present in the blood of these patients. Furthermore, the number of cells analysed were far fewer than we report in this study and may have been insufficient for detection.
Consistent with our previous work (Terry et al., 2009 ), we were unable to detect PrP Sc in the blood from all scrapie-infected sheep. Two of the five sheep sampled in the MHC II DQ study were consistently negative for PrP Sc in the blood and PrP Sc could not be detected in all sheep at the clinical end stage of disease (data not shown). However, preliminary data, resulting from the study presented here, showed that in a proportion of sheep, PrP Sc could be detected in the blood of these 'test negative' animals following enrichment of the appropriate fraction. Indeed, the percentage of clinical sheep (of assorted genotypes) giving a positive signal following enrichment of either MHC II DQ, VPM8, CD11b, or CD11c increased from 57.1% to 71.4% (n = 28). This has potential implications for the development of diagnostics, since targeting the positive cell population for testing would increase the sensitivity of the assay. However, some sheep remained PrP Sc-negative in the blood despite B cell enrichment. Likewise, transfusion studies in sheep have indicated that infectivity is not present in the blood from all sheep, although transmission rates increased from 33% to 80% with increasing incubation period of the donor (Houston et al., 2008) . To this end, PrP
Sc and/or infectivity may not be present in all animals and at all time points during infection. Furthermore, it is not known in this study whether the PrP Sc detected is synonymous with infectivity: an issue which is currently under investigation.
In sheep, two subpopulations of B lymphocytes have been described with apparent anatomical distributions and functional characteristics that can be differentiated based on the expression of CD11b and CD11c (Chevallier et al., 1998; Gupta et al., 1998) , or CD21 and CD62L (Gupta et al., 1998; Young et al., 1997) . In line with these distinctions, we show a direct association of PrP Sc in blood with the CD11b/CD11c-expressing subset of B lymphocytes. However, we observed variability in the partitioning of PrP Sc in the corresponding CD21 and CD62L populations-a finding that would indicate that the delineation of subsets by these cell surface markers is not as precise as previously suggested. Indeed, others have reported that 70% of CD21 cells express CD62L (Young et al., 1997) which is significantly higher than our observation (45.7%). The reason for this discrepancy is unclear although it may be related to disease status, the age of the sheep or different cell processing regimes. Indeed, CD21 expression decreases with age (Young et al., 1999) and leucocyte activation can modify CD62-L expression (Munro et al., 1996) . Sheep CD11b/CD11c and CD21/CD62L B cells subsets have been likened to murine B-1 and B-2 cells, respectively (Chevallier et al., 1998) . In mice, these cell lineages appear to perform distinct functions: B-1 cells are a major source of natural IgM antibodies responding primarily to self and repetitive antigen in a T-cellindependent manner and are believed to form the first line of defence in an immune response . These cells are also restricted to specific anatomical locations, including the spleen and the peritoneal cavity as well as the blood (Kearney, 2005) . On the other hand, B-2 cells, or conventional B cells, require T cells for costimulation and differentiation into plasma cells or memory cells. They also undergo affinity maturation to increase receptor diversification further. Interestingly, mice in which the CD19 molecule has been deleted and therefore have reduced numbers of B-1 cells demonstrate a significantly shorter incubation period following peripheral challenge with prions compared to both wild type controls and CD22 −/− mice, which have reduced number of B-2 cells (von Poser- Klein et al., 2008) . While this observation was explained by the reduced distance observed between follicular dendritic cells (FDC) and the neighbouring nerve fibres of the peripheral nervous system, it is tempting to speculate that murine B-1 cells might also accumulate prions in the blood and, in their absence, may have a direct effect on disease pathogenesis. PrP Sc aggregates are likely candidates for recognition by B-1 cells, which favour multimeric antigenic sequences , and many studies have demonstrated predominant IgM responses following repeated immunisation with prions (Korth et al., 1997; Paramithiotis et al., 2003; Tayebi et al., 2004) . Others have also suggested that B cells might play a role in disease pathogenesis (Frigg et al., 1999; Klein et al., 1997 Klein et al., , 1998 , although it is still unclear whether this goes beyond the secretion of lymphotoxin, which serves to facilitate the maturation of FDC.
In sheep naturally infected with scrapie, haematogenous dissemination might explain the progressive appearance of prions in peripheral lymphoid tissue during the course of the disease (Jeffrey and Gonzalez, 2007) . During scrapie infection, prions are first detected in the ileal Peyers Patches (iPP) in lambs as young as 2 months of age (Andreoletti et al., 2000) , which is consistent with uptake from the gastrointestinal tract following oral exposure. Subsequently, prions accumulate in other gut-associated lymphoid tissue and eventually spread to distant peripheral lymphoid tissue (van Keulen et al., 2006) . In young sheep, the iPP represent a major site for B-cell production and infected B cells originating from this site could transfer prion infectivity to other regions of the LRS. However, CD11b cells and their murine B-1 cell equivalents are predominantly distributed in the blood and marginal zone of the spleen (Chevallier et al., 1998; Bazin et al., 1982) , indicating that these cells are unlikely to re-enter secondary lymphoid tissues. This is supported by their lack of expression of the homing molecule CD62L (Gupta et al., 1998) . Nevertheless, lymphocytes lacking CD62L do migrate to the spleen (Tang et al., 1998) , suggesting that CD11b cells might be at least partly responsible for the high infectivity levels in spleen during prion disease in sheep (Andreoletti et al., 2000; van Keulen et al., 1996 van Keulen et al., , 2006 . Moreover, substantial accumulations of PrP Sc have been detected in the splenic marginal zone of sheep with scrapie (Sorby et al., 2009) , which is consistent with the localisation of CD11b B -1 type cells (Chevallier et al., 1998) .
Several other studies have implicated the dendritic cell as a likely candidate for sequestration and transport of PrP Sc though the LRS (Aucouturier et al., 2001; Flores-Langarica et al., 2009; Huang et al., 2002; Luhr et al., 2002; Sethi et al., 2007) . Indeed, our previous study showed that the blood-borne prion-infected cells could be as few as 0.005-0.1% of total PBMC, which is consistent with the paucity of DC in the blood (Freudenthal and Bhardwaj, 1990) . However, most DCs are retained in the lymph node, and their exit and return to the blood is a rare event (Randolph et al., 2008) . These rare cells have not been isolated and characterised in sheep, and therefore, the markers they are likely to express are unknown. However, DCs do express cell surface molecules that overlap with those of other lineages, most notably CD11c and CD11b, so we cannot rule out the possibility that we have copurified blood DC in our fractions.
In summary, we have shown that B cells or a subpopulation of B lymphocytes concentrates PrP Sc in the blood of scrapie-infected sheep. Whether they are important to disease progression has not been elucidated, but these studies provide a starting point for further investigation on the role of blood cells in disease pathogenesis in sheep and prion diseases in other species.
Materials and methods
Animals
All animal procedures were approved by the Home Office under the Animals (Scientific Procedures) Act 1986. Peripheral blood was collected by jugular venipuncture from scrapie-infected, BSE-infected, and uninfected control sheep.
Blood from sheep naturally infected with scrapie was sourced from the Veterinary Laboratories Agency scrapie flock, which was established in 1995 through the purchase of siblings and offspring of various breeds and genotypes born to scrapie-infected dams from breeding and commercial flocks. The first confirmed case of scrapie to a flock-born sheep was in 1998. The breeding programme for this flock aims to ensure a continued population of fully susceptible genotypes to maintain a high infection pressure. Currently, all sheep born in the flock and carrying the scrapie-susceptible VRQ/VRQ genotype develop clinical disease aged between 16 months and 3.3 years. Similarly, all ARQ/VRQ sheep born in the flock develop clinical disease aged between 17 months and 4.1 years.
The majority of the assays described in this report was performed on blood sampled from VRQ/VRQ (n = 32) and ARQ/VRQ (n = 6) clinically affected sheep at post mortem, with mean age at death of 23 months (range 21-27 months) and 27 months (range 24-32 months), respectively. Sheep sampled during the preclinical phase are described in the text and summarised in Table 1 . For sheep with BSE, Romney or Suffolk females were orally challenged with a pool of BSE inoculums, which had been created from the brainstems of 20 histologically confirmed clinical cases of BSE in cattle. Blood from uninfected age-and genotype-matched diseasefree animals was obtained from a flock that has been stocked with animals originating from New Zealand and maintained free of TSE disease by strict biosecurity control.
Isolation of PBMC from sheep blood and separation of cell subpopulations
Blood was collected by jugular venipuncture and mixed with EDTA as the anticoagulant. Occasionally, animals showing clinical signs of disease were sedated with sodium thiopentone according to Home Office guidelines before blood collection. For collection of blood at post mortem, sheep were euthanised with 10 ml of somulose and the blood obtained by exsanguination. Buffy coats were then isolated by centrifugation at 1400 × g at 20°C for 50 minutes. The buffy coat was diluted 1:3 with cell wash buffer (Dulbecco's phosphate-buffered saline (PBS) containing 0.002% EDTA, 0.5% BSA, and 0.1% sodium azide). All buffers were used at ambient temperature unless otherwise stated. Twenty milliliters of the cell suspension was carefully layered onto 10 ml of Nycoprep™ (1.077 g/ml; Axis-Shield PoC AS, Oslo) and centrifuged at 600 × g for 30 minutes at 20°C without braking. The PBMCs were then harvested from the upper interface and were gently washed. To remove residual platelets, the cells were layered over a second density gradient of OptiPrep™ (1.063 g/ml; Axis-Shield PoC AS, Oslo), and again, the cells were gently washed. Finally, the pellet was resuspended in 2 ml of ammonium chloride lysis buffer (155 mM NH 4 Cl, 10 mM NaHCO 3 , 0.1 mM EDTA, pH 7.2-7.4) for 1 minute, and then up to 40 ml of wash buffer was added immediately. The cells were then centrifuged at 240 × g at 20°C for 20 minutes.
For cell separation based on cell surface molecule expression, 1 × 10 8 PBMCs were incubated with prepared antibody in dilution buffer (Dulbecco's PBS containing 1% BSA and 0.1% sodium azide) for 20 minutes at 4°C. Unbound antibody was removed by addition of cell wash buffer and centrifugation at 240 × g for 5 minutes. For cell concentration, 200 µl of MACS magnetic beads conjugated to isotypematched secondary antibody (Miltenyi Biotech) were added and incubated for 15 minutes at 4°C. Following a second wash, the cells were incubated with a second, isotype-matched secondary antibody conjugated to phycoerythrin to assess the purity of the subsequent unseparated, depleted (unlabelled), and concentrated (labelled) cell fractions. Cell separation was carried out according to the protocol detailed for LS columns (Miltenyi Biotech). The unseparated, depleted, and concentrated cells were counted and collected at equivalent cell numbers. Cells were frozen at −80°C before immunoassay for PrP Sc . The purity of each of the fractions was determined by flow cytometry, and the contamination was less than 5% in the depleted fraction, and the purity was greater than 90% in the concentrated fraction.
Antibodies and flow cytometric analysis
Antibodies used for cell separations included anti-sheep MHC II DQ monomorphic (38.27; Serotec) (Puri et al., 1985) , CD2 (MUC2A; VMRD inc.) (Mackay et al., 1989) , VPM8 (sIg) (gift from Barbara Blacklaws) (Yirrell et al., 1991) , CD14 (Tük4; Acris Antibodies) (Gupta et al., 1996) , anti-bovine CD21 (CC21; Serotec) (Howard et al., 1991; Naessens et al., 1990) anti-bovine CD11b (CC126; Serotec) (Howard and Naessens, 1993; Naessens et al., 1993) , anti-ovine CD11c (OM1; Gift from Barbara Blacklaws with permission from Michel Olivier) (Gupta et al., 1993) , and anti-bovine CD62L (CC32; Serotec) (Sopp and Howard, 2001 ). Anti-PrP antibodies used were FH11 (residues 54-57), SAF32 (octapeptide repeat 79-92), 6H4 (144-152), and Sha31 (145-152).
For two-colour cytometric analysis PBMC were labelled with antiPrP antibodies or antibodies specific for cell surface markers as stated (or normal mouse serum). To determine coexpression of surface markers on PBMC populations, blood was taken from five scrapieexposed sheep approximately 17 months of age. To avoid using the same antibody isotypes, anti-ovine MHC II (SW73.2; Acris Antibodies) (Hopkins et al., 1986) and anti-CD11c (BAQ153A; VMRD Inc.) (Howard et al., 1991) antibodies were included in this series of experiments. Briefly, the cell pellets containing 10 6 cells were gently resuspended and incubated with antibody at 4°C for 20 minutes. Excess antibody was washed off, and labelling was detected by incubation with anti-mouse isotype-matched secondary antibodies conjugated to phycoerythrin (BD Pharmingen) and FITC (BD Pharmingen). The cells were finally washed and assessed for cell surface labelling using 2-colour flow cytometry (EPICS, Coulter).
Where the antibodies were of the same subclass, labelling was done sequentially with a 30-minute blocking step using 5 mg/ml normal mouse serum in PBS before probing the cells with the second antisubset antibody and the isotype-matched, fluorochrome-conjugated secondary antibody. The labelling of the subset antibodies was also assessed by onecolour flow cytometry to ensure that the two-colour protocol did not alter results.
For three-colour flow cytometric analysis, PBMCs were labelled with VPM8 (sIg), anti-CD11b (CC126; Serotec), and anti-CD11c (BAQ153A; VMRD Inc.), and labelling was detected by anti-mouse isotype-matched secondary antibodies conjugated to FITC, PE, and PerCP-Cy5.5, respectively. PBMCs were also analysed using singlecolour and two-colour flow cytometry to ensure the three-colour protocol did not alter the results.
Where indicated, percentages of subset positive cells were calculated by the percentage of dual positive cells/total number of subset of interest positive cells. For example for the percentage of B cells that also express MHC II DQ, the calculation would be 20/20.5× 100% (as shown Fig. 3Aiii ). The figures quoted in the text are means of five individual sheep.
Immunoassay for the detection of PrP Sc
The assay for the detection of PrP Sc associated with PBMC has been previously described (Terry et al., 2009) and is a modified protocol of the IDEXX HerdChek CWD antigen EIA. Briefly, cell pellets were frozen, thawed, and diluted in water. Thawed cells were ribolysed, homogenate removed, and mixed with working plate diluent. Samples were then analysed according to the manufacturer's instructions, except that the plate was incubated for 2.5 hours with agitation at room temperature and then washed six times with wash solution 1 (provided in the kit). Absorbance was read at 450 nm and 620 nm using a Victor multiwell plate reader (Perkin-Elmer). Depending on the number of cells enriched, analysis of the fractions was single well, in duplicate or triplicate. Cells from five uninfected genotype-matched sheep were analysed simultaneously.
Statistical analysis
To determine statistically significant differences between the absorbance values for each of the cell fractions isolated from scrapieexposed sheep, a two-way analysis of variance (ANOVA) was used with sheep and cell fractions as the main effects and the interaction as the error term. Differences between each pair of fractions were determined by t tests using the ANOVA error mean square. In addition, t tests allowing for unequal variance were used to compare cell fractions with PBMCs from scrapie-free sheep.
